electroCore, Inc. (ECOR) Stock Analysis

Price updated 4 days ago · SEC data refreshed 3 months ago · Not investment advice

electroCore, Inc.

ECOR Healthcare Medical Devices📄 SEC filings ↗
Valuation N/A
▾ What's in the 55/100 risk score? (higher = riskier)
Fundamental health (43%) 62/100 → +26.6
leverage 62/100
Smart money (short interest + insider buying) (31%) 65/100 → +20.4
Macro backdrop (VIX, curve, credit, fear/greed + week-over-week momentum) (26%) 33/100 → +8.5
Total55/100

Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend). See the Financial Health section for the full balance-sheet read.

💵 Price $9.62 · 4 days ago 📄 Financials SEC EDGAR · refreshed 3 months ago

How to read ECOR (pre-profit growth)

This company is reinvesting instead of generating profit, so a standard DCF cannot price it. The useful question is whether the growth the market is paying for is achievable — and whether the company can fund itself until then.

Where to start — the sections that matter most for this stock
  1. 1 Reverse-DCF — the growth the price demands ↓
    It shows exactly how fast the business must grow to justify today's price. Compare that to what comparable companies have actually achieved.
  2. 2 Cash runway ↓
    Can it reach profitability before it has to raise money and dilute shareholders?
  3. 3 Interactive calculator ↓
    Set your own growth + margin assumptions and see what the business would be worth if you are right.
Or — what are you trying to decide?
A note on process: fear-driven decisions — including fear of missing out — tend to be the expensive ones. A stock up 10% a day for three days is excitement, not evidence. Whichever reader you are, the data below is there to be checked before anything is decided.
🚀
"It's surging — should I chase it?"
The momentum / FOMO trade. Before you chase, see whether the people who know it best are quietly selling into the rally.
🏷️
"Is it a cheap bargain?"
The deep-value trade. How far below assets and our value it trades — and whether it's cheap for a reason.
ⓘ Using the right valuation lens for this business type

Standard DCF doesn't fit ECOR well — but that's expected for this kind of business. The Rule of 40 (Pre-Profit Growth) Lens below uses the metrics actually used by analysts who value medical devices. Reverse DCF + Football Field also work as cross-checks.

Loading insider & short-seller data…
Checking filings for failure warnings…

Quality & solvency checks

Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.

Altman Z-Score?Altman Z-Score — A bankruptcy-risk score combining 5 financial ratios into one number. Predictive of bankruptcy within 2 years.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
Not available for this filer

The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.

Piotroski F-Score?Piotroski F-Score — A 9-point quality checklist scoring profitability, leverage, and operating efficiency.
Why it matters: High score = fundamentals improving. Low score = deteriorating. Especially powerful for filtering cheap stocks: cheap + high F-score historically outperforms; cheap + low F-score is often a value trap.
Reference: 7–9 = strong · 4–6 = mediocre · 0–3 = weak
Full explanation →
3 / 9
Weak
▾ The checks — what passed, what didn't (and what we couldn't measure)
  • Positive net income
    Net income -$14.0M in FY2025.
    Why this matters: Does the company actually earn a profit? Sustained losses eventually force it to raise money — diluting you — or take on debt.
  • Positive operating cash flow
    Operating cash flow -$8.2M (was -$6.9M the prior year).
    Why this matters: Profit can be an accounting figure; cash from running the business is harder to fake. Negative operating cash flow means the core business consumes cash and must be funded externally.
  • Cash flow backs up reported profit
    Operating cash flow -$8.2M vs net income -$14.0M.
  • Return on assets improving
    Return on assets -74.8% vs -58.1% a year ago.
    Why this matters: Is the company squeezing more profit out of each dollar of assets than last year? Rising = getting more efficient; falling = the opposite.
  • Debt load (vs assets)
    Total debt is 41.6% of assets vs 0.0% a year ago ($7.8M of $18.7M assets).
    Why this matters: Rising debt relative to assets means more risk and more cash going to interest instead of shareholders. Falling debt is a sign of strengthening.
  • Short-term liquidity (current ratio)
    Current ratio 1.38x vs 1.78x a year ago.
    Why this matters: The current ratio compares assets it can turn to cash within a year against bills due within a year. Below 1.0 means it may struggle to cover near-term obligations.
  • Share count (dilution)
    Share count rose 13.4% (0.0M → 0.0M year-over-year).
    Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
  • Pricing power (gross margin)
    Gross margin 86.8% vs 85.0% a year ago.
  • Sales per asset (asset turnover)
    Asset turnover 1.72x vs 1.23x a year ago.

Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.

Cash Runway
10 mo
TIGHT — under a year; likely needs to raise capital soon

Plain English: the company holds about $7M in cash and is burning roughly $8M/year in operations. At that pace, the cash lasts 10 mo before it must raise capital (diluting shareholders), take on debt, or cut spending.

Assumes constant burn and ignores financing/asset sales. For pre-profit biotech and growth companies, this matters more than a DCF — a great drug pipeline is worthless if they run out of money before approval.

Price$9.62
Model IVNot applicable — DCF couldn't price this stock. The other valuation lenses on this page (reverse-DCF, peers, sector lens — whichever apply to this filer) carry the read instead.

A standard discounted cash flow?DCF — Discounted Cash Flow — sums up all future cash a business will produce, adjusted for the fact that future dollars are worth less than dollars today.
Why it matters: It is the most fundamentally honest valuation method when applicable — but only works for companies with predictable, positive cash flow.
Reference: Best for: mature, profitable businesses. Fails for: pre-profit growth, banks, REITs.
Full explanation →
(DCF) valuation is not meaningful for electroCore, Inc. due to its consistently negative operating cash flow and net income, indicating a cash-burning growth stage. Investors are likely focused on the company's rapid revenue growth (55.7%/yr) and expanding gross margins as indicators of future potential. The market may be assigning value to the potential for broader adoption of its non-invasive vagus nerve stimulation technology, which is not in the model. The primary quantifiable risk is the continued negative operating cash flow, which necessitates ongoing financing.

⚠️ FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.

As of 3 months ago

Anatomy of a share

What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.

Per-share economics aren't reliable for this filer. Its income statement or share count isn't fully reported to SEC EDGAR (common for foreign private issuers and thinly-disclosed OTC names), so we don't break it down per share here — the figures would be misleading. See the financial tables below for what is reported.

What you actually need to decide

Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.

🐂 The Bull Case
Operating cash flow must turn positive to demonstrate a sustainable business model and reduce reliance on external financing.
🐻 The Bear Case
Continued negative operating cash flow, as seen in the latest period, implies ongoing cash burn and potential dilution from future equity raises.
📌 Signposts to watch — update your view as these print
  • Acceleration in revenue growth rate
  • Improvement in operating cash flow towards positive
  • New product approvals or expanded indications

The trend, in plain numbers (FY2024 → FY2025, latest reported)

Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.

✅ Improving
  • Revenue grew +27% to $32.0M.
  • Gross margin improved to 87% (+2 pts).
⚠ Worsening
  • Free cash flow is negative at -$10.2M — the cash burn widened vs last year.
  • Still unprofitable at -$14.0M — loss widening.

Management & Leadership

Daniel Goldberger has served as electroCore's Chief Executive Officer since 2016, leading the company in developing its non-invasive vagus nerve stimulation therapies. J.P. Errico is the founder and serves as Chairman of the Board.

Daniel Goldberger
Chief Executive Officer
J.P. Errico
Founder and Chairman of the Board

What They Make

electroCore, Inc. develops and commercializes non-invasive vagus nerve stimulation (nVNS) therapies for the acute and preventive treatment of migraine and cluster headache, primarily selling to healthcare providers and patients.

End Markets

Migraine treatmentCluster headache treatmentNeurological disorders

Revenue Drivers

gammaCore device sales
Prescription volume growth
Geographic expansion
Beta: 1.92

Why Is It Priced Like This?

Why Customers Pay

Non-invasive treatment option
Drug-free pain relief
Portable and easy to use
No discounted-cash-flow value for this filer This company's reported free cash flow is negative, so a discounted-cash-flow valuation has no positive cash stream to discount. That is a fact about the business, not missing data — the reported figures below are complete.

What we use instead: earnings (P/E, EV/EBIT), book value (P/B) — computed from the figures this company does report, shown in the sections below. Those numbers are unaffected by the missing cash-flow data.

The market is pricing electroCore based on its significant revenue growth of 55.7%/yr and expanding gross margins (74.6% to 86.8%), rather than current profitability, as net income and operating cash flow are negative. The market may be assigning value to the potential for new indications or broader insurance coverage for nVNS technology, which is not in the model. Investors are likely betting on the company's ability to scale its technology and achieve profitability in the future.

Business Model & Valuation

How They Make Money

gammaCore device sales
Prescription volume growth
Geographic expansion

Growth / Revenue DCF

Negative free cash flow: revenue/margin growth model used - standard FCF DCF is unreliable for companies still scaling.

Show advanced inputs
Revenue Growth50.0%

What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.

Maturity & Competitive Position

Growth / re-investment phase

Moat Signals

Proprietary nVNS technology
FDA/regulatory clearances
Clinical evidence for efficacy

Revenue has been growing at 55.7%/yr over four years, from $5M to $32M.

Geography & Markets

electroCore, Inc. is headquartered in the US and operates internationally, primarily focusing on markets where its nVNS technology is approved. Specific geographic revenue mix is not available from current data sources.

Geographic Risks

Regulatory approval and reimbursement risk in new markets
Concentration risk on a single core technology

Market Signals

These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.

Model neutral, tape bullish
RSI?RSI — Relative Strength Index — a 0-100 momentum gauge. Above 70 = overbought; below 30 = oversold.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation →
(14)
78.1OverboughtBought up hard recently — stretched; pullbacks are common from here.
MACD?MACD — Moving Average Convergence Divergence — compares a fast and a slow price trend to gauge momentum direction.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →
BullishLine above signalThe fast trend is above the slow trend — short-term momentum is currently upward.
50-Day Average$6.60Price above (+45.8%)Price above its 50-day average = near-term uptrend.
200-Day Average$5.80Price aboveThe 200-day line is the long-term trend divider — above it is generally considered a bull market for the stock.
50 vs 200 CrossGolden50-day above 200-dayA "golden cross" — the medium trend has overtaken the long trend (often read as bullish).

Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.

Data Quality & Risk Flags (4 notes — click to expand/collapse)

Guardrail Notes (4)
  • FCF negative: revenue/margin growth model projects future cash flows from revenue trajectory.
  • Illiquidity discount 15% applied (small/micro-cap — harder to exit, demand a margin).
  • Extreme valuation (P/IV withheld — see the note above); output dominated by data/units issue (often a multi-class share-count mismatch). Suppressed.
  • DATA UNAVAILABLE: per-share values suppressed due to missing/unreliable shares data.

Financial Statements (5-year tables — click to expand)

From electroCore, Inc.'s SEC filings (EDGAR).

Income (5yr)

YearRevenueNet IncomeEPS
202532.0M-14.0M$-1.65
202425.2M-11.9M$-1.59
202316.0M-18.8M$-3.42
20228.6M-22.2M$-4.69
20215.5M-17.2M$-4.36

Cash Flow (5yr)

YearOperating CFCapEx− SBC & adj.Free Cash Flow
2025 -8.2M 66,000 1.9M -10.2M
2024 -6.9M 1.9M -8.8M
2023 -14.7M 206,000 1.7M -16.6M
2022 -16.6M 2.7M -19.3M
2021 -13.6M 3.3M -16.9M

How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: -8.2M − 66,000 − 1.9M (SBC & adj.) = -10.2M. This is the same owner-earnings FCF definition the valuation model uses, though the DCF's starting value is a projected from revenue × terminal margin, not this single year.

Balance Sheet

Total Assets18.7M
Total Liabilities20.4M
Equity-1.7M
Total Debt7.8M

Similar companies worth a look

Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.

PG
Methodology by Pouyan Golshani, MD — founder of Gighz. Savng was built by a physician for busy professionals: every number on this page comes from SEC filings (EDGAR) and FINRA data through transparent, rules-based models — no analyst opinions, no hidden inputs. How we calculate every number →
⚠️ Not investment advice. Automated model outputs, last refreshed May 30, 2026 (the analysis-refresh date, not the latest filing period). All models have blind spots. Full disclaimer →
🔔 Follow $ECOR — free insider alerts
One email when an insider buys $ECOR on the open market with their own cash — or notably sells outside a scheduled plan. Routine and automated trades filtered out. Follow up to 3 stocks free; Portfolio Watch covers your whole list plus valuation & risk alerts. Double opt-in, unsubscribe anytime.